Déclarations et communiqués des organismes de réglementation et de nos partenaires

Biomarin provides updated 4-year data from their Phase 1/2 Valoctocogene Roxaparvovec gene therapy trial in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual Summit. To read the full press release, please click here.
juin 2020

EHC-EAHAD Joint position statement on Gene Therapy
mai 2020